Anandamide Attenuates Th-17 Cell-Mediated Delayed-Type Hypersensitivity Response by Triggering IL-10 Production and Consequent microRNA Induction

thumbnail

“Endogenous cannabinoids [endocannabinoids] are lipid signaling molecules that have been shown to modulate immune functions..

Cannabinoids are compounds derived from the Cannabis sativa plant and exert many effects on the immune system. Cannabinoids have potential as therapeutic agents in several different disease conditions, including experimental autoimmune hepatitis, Multiple Sclerosis, and Graft vs. Host Disease…

This report suggested a role of the endogenous cannabinoid system in regulation of allergic inflammation.

These studies also suggest that endogenous cannabinoid system is one of the homeostatic mechanisms that the body employs to down-regulate immune response to foreign antigens as well as combat autoimmunity.

Targeting of this system could yield valuable therapeutics in the future.”

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0093954

Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis.

“Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) [Sativex®] is an oromucosal spray formulation that contains principally THC and CBD at an approximately 1:1 fixed ratio, derived from cloned Cannabis sativa L. plants.

The main active substance, THC, acts as a partial agonist at human cannabinoid receptors (CB1 and CB2)…

THC/CBD is approved in a number of countries, including Germany and the UK, as an add-on treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy.

In the largest multinational clinical trial that evaluated the approved THC/CBD regimen in this population, 12 weeks’ double-blind treatment with THC/CBD significantly reduced spasticity severity (primary endpoint) compared with placebo in patients who achieved a clinically significant improvement in spasticity after 4 weeks’ single-blind THC/CBD treatment, as assessed by a patient-rated numerical rating scale.

A significantly greater proportion of THC/CBD than placebo recipients achieved a ≥30 % reduction (a clinically relevant reduction) in spasticity severity. The efficacy of THC/CBD has been also shown in at least one everyday clinical practice study (MOVE 2). THC/CBD was generally well tolerated in clinical trials. Dizziness and fatigue were reported most frequently during the first 4 weeks of treatment and resolved within a few days even with continued treatment.

Thus, add-on THC/CBD is a useful symptomatic treatment option for its approved indication.”

http://www.ncbi.nlm.nih.gov/pubmed/24671907

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis

“…exogenous CB1agonists can provide significant neuroprotection from the consequences of inflammatory CNS disease… Therefore, in addition to symptom management, cannabis may also slow the neurodegenerative processes that ultimately lead to chronic disability in multiple sclerosis and probably other diseases.

The results of this study are important because they suggest that in addition to symptom management, cannabinoids offer the potential to slow the progression of a disease that as yet has no satisfactory treatment.”

http://brain.oxfordjournals.org/content/126/10/2191.full

Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology.

“Clinicians might offer oral cannabis extract for spasticity symptoms and pain (excluding central neuropathic pain) (Level A). Clinicians might offer tetrahydrocannabinol for spasticity symptoms and pain (excluding central neuropathic pain) (Level B). Clinicians should counsel patients that these agents are probably ineffective for objective spasticity (short-term)/tremor (Level B) and possibly effective for spasticity and pain (long-term) (Level C). Clinicians might offer Sativex oromucosal cannabinoid spray (nabiximols) for spasticity symptoms, pain, and urinary frequency (Level B). Clinicians should counsel patients that these agents are probably ineffective for objective spasticity/urinary incontinence (Level B). Clinicians might choose not to offer these agents for tremor (Level C). Clinicians might counsel patients that magnetic therapy is probably effective for fatigue and probably ineffective for depression (Level B); fish oil is probably ineffective for relapses, disability, fatigue, MRI lesions, and quality of life (QOL) (Level B); ginkgo biloba is ineffective for cognition (Level A) and possibly effective for fatigue (Level C); reflexology is possibly effective for paresthesia (Level C); Cari Loder regimen is possibly ineffective for disability, symptoms, depression, and fatigue (Level C); and bee sting therapy is possibly ineffective for relapses, disability, fatigue, lesion burden/volume, and health-related QOL (Level C)…”

http://www.ncbi.nlm.nih.gov/pubmed/24663230

Marijuana pills and sprays ease MS symptoms

Marijuana leaf

“Multiple sclerosis is characterized by disrupted communication between the brain and the body, resulting in symptoms ranging from blurred vision to muscle weakness and pain. There is no cure for the condition, and therapies have proven difficult, as many have serious side effects.

But now, relief may come in the form of a medical marijuana pill.”

http://www.medicalnewstoday.com/articles/274517.php

AAN calls oral cannabinoids effective for MS pain, spasticity

“An expert panel organized by the American Academy of Neurology called oral cannabis extract the only complementary and alternative medicine unequivocally effective for helping patients with multiple sclerosis, specifically easing their pain and symptoms of spasticity, medicine possibly for as long as 1 year of treatment.”

http://www.clinicalpsychiatrynews.com/cme/click-for-credit-articles/single-article/aan-calls-oral-cannabinoids-effective-for-ms-pain-spasticity/6ca42663d197581d76107390a304ec4d.html

Study: Marijuana only alternative therapy showing promise for MS patients

MarijuanaGrow-Medicinal

“Researchers said medical marijuana seems to be the only “alternative therapy” showing promise for helping those with multiple sclerosis.

Officials at Oregon Health and Science University said research shows therapies like massage and acupuncture aren’t as effective as medical marijuana.”

http://kfor.com/2014/03/24/study-marijuana-only-alternative-therapy-showing-promise-for-ms-patients-massage-acupuncture-dont/

Neurologists Say Medical Marijuana Effective in Treating MS

Image courtesy of GW Pharmaceuticals

“The American Academy of Neurology has become one of the first medical organizations in the U.S. to endorse the use of medical marijuana.

In new guidelines published in the journal Neurology, the Academy said oral cannabis, medical marijuana pills and medical marijuana spray may help ease symptoms of muscle spasticity and frequent urination caused by multiple sclerosis (MS).”

http://americannewsreport.com/nationalpainreport/neurologists-say-medical-marijuana-effective-treating-ms-8823383.html

Smoked Cannabis Reduces Some Symptoms of Multiple Sclerosis

“Controlled trial shows improved spasticity, reduced pain after smoking medical marijuana

A clinical study of 30 adult patients with multiple sclerosis (MS) at the University of California, San Diego School of Medicine has shown that smoked cannabis may be an effective treatment for spasticity – a common and disabling symptom of this neurological disease.”

http://health.ucsd.edu/news/releases/Pages/2012-05-14-smoked-cannabis-reduces-symptoms-of-multiple-sclerosis.aspx

Medical marijuana

“Medical marijuana eases some MS symptoms, neurologists report” http://www.latimes.com/science/sciencenow/la-sci-sn-treating-ms-with-cannabis-20140324,0,2596095.story